ストックスクリーナーアプリを入手
17.48
2.81%
-0.50
前日終値:
$17.98
開ける：
$17.98
24時間の取引高:
421.98K
Relative Volume:
0.30
時価総額：
$1.72B
収益：
-
当期純損益:
$-44.84M
株価収益率:
-37.19
EPS:
-0.47
ネットキャッシュフロー:
$-44.23M
1週間 パフォーマンス:
-1.16%
1か月 パフォーマンス:
+2.25%
6か月 パフォーマンス:
+46.60%
1年 パフォーマンス:
+82.70%
1日の値動き範囲:
$17.46
$18.00
1週間の範囲:
$17.07
$18.00
52週間の値動き範囲:
$9.52
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
名前
Ars Pharmaceuticals Inc
セクター
電話
858-771-9307
住所
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
SPRY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
17.48 | 1.75B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
376.45 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.38 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
426.74 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
668.29 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
294.56 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2025-02-10 | 開始されました | Oppenheimer | Outperform |
| 2024-08-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-08-13 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | 繰り返されました | Leerink Partners | Outperform |
| 2024-07-25 | 開始されました | Raymond James | Outperform |
| 2024-03-05 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 開始されました | Wedbush | Outperform |
| 2023-01-03 | 開始されました | William Blair | Outperform |
| 2022-12-13 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Ars Pharmaceuticals Inc (SPRY) 最新ニュース
ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results - GlobeNewswire
ARS Pharmaceuticals Q2 Earnings Call: Anaphylaxis Treatment Leader Reports Latest Financial Results - Stock Titan
What drives ARS Pharmaceuticals Inc. stock priceCapitalize on emerging trends for profits - Jammu Links News
How volatile is ARS Pharmaceuticals Inc. stock compared to the marketBuild a portfolio that outperforms the market - Jammu Links News
How does ARS Pharmaceuticals Inc. compare to its industry peersAchieve breakthrough financial results today - Jammu Links News
What institutional investors are buying ARS Pharmaceuticals Inc. stockMarket-beating returns - Jammu Links News
Is ARS Pharmaceuticals Inc. a growth stock or a value stockMassive portfolio appreciation - Jammu Links News
What analysts say about ARS Pharmaceuticals Inc. stockIdentify undervalued stocks poised to rally - Jammu Links News
Is ARS Pharmaceuticals Inc. stock overvalued or undervaluedBuild a portfolio that grows with the market - Jammu Links News
What makes ARS Pharmaceuticals Inc. stock price move sharplyHigh-profit capital plays - Jammu Links News
How does ARS Pharmaceuticals Inc. generate profit in a changing economyMarket-crushing stock picks - Jammu Links News
How strong is ARS Pharmaceuticals Inc. company’s balance sheetTriple-digit profit margins - Jammu Links News
Does ARS Pharmaceuticals Inc. stock perform well during market downturnsStay ahead with advanced stock screening tools - Jammu Links News
What is the risk reward ratio of investing in ARS Pharmaceuticals Inc. stockGet expert alerts on market-moving stocks - Jammu Links News
What are ARS Pharmaceuticals Inc. company’s key revenue driversDaily Trading Strategy For Smart Trading - jammulinksnews.com
What is ARS Pharmaceuticals Inc. company’s growth strategyBreakout Stocks Watchlist That Work - jammulinksnews.com
ARS Pharmaceuticals Inc expected to post a loss of 47 cents a shareEarnings Preview - TradingView
Why is ARS Pharmaceuticals Inc. stock attracting strong analyst attentionDaily Trading Picks With High Returns - Jammu Links News
Here's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price Strength - Yahoo Finance
Quant Models Detect Momentum Reversal in ARS Pharmaceuticals Inc.Trend Analysis for Safer Trades Gains Popularity - metal.it
ARS Pharmaceuticals Inc. Stock Approaches Key Moving AverageConservative Entry for High Return Setup Backed - beatles.ru
Analysts Estimate ARS Pharmaceuticals, Inc. (SPRY) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
ARS Pharmaceuticals Inc.’s Price Action Aligns with Quant SignalsTarget Return Focused Trade Insights Shared - metal.it
What institutions are buying ARS Pharmaceuticals Inc. stock nowReal Time Stock Movement Analysis Indicates Breakout - metal.it
When is ARS Pharmaceuticals Inc. stock expected to show significant growthProven strategies for superior portfolio growth - Jammu Links News
Published on: 2025-07-28 04:26:33 - jammulinksnews.com
Should I hold or sell ARS Pharmaceuticals Inc. stock in 2025Consistent double returns - Jammu Links News
ARS Pharmaceuticals Inc. Stock Analysis and ForecastBreakthrough financial growth - PrintWeekIndia
Is ARS Pharmaceuticals Inc. a good long term investmentTriple-digit return opportunities - PrintWeekIndia
Ars Pharmaceuticals Inc (SPRY) 財務データ
収益
当期純利益
現金流量
EPS
0.53%
0.00%
大文字化:
|
ボリューム (24 時間):